Our lab is focused on the development of drug compounds that regulate the translation of the protein excitatory amino-acid transporter 2 (EAAT2). Increased expression of this protein has shown potential for the treatment of neurological disease and disorders including amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy and depression. My project focuses on defining the compound mechanism of action and testing new optimized compound analogs for enhanced efficacy in the above disease models. While we have a strong focus on clinical translation research, as part of this current project, the basic cellular mechanism by which EAAT2 mRNA is regulated at the translational level will also be identified.
Takahashi K, Foster JB, Lin, CLG. (2015) Glutamate transporter EAAT2: regulation, function, and potential as a therapeutic target for neurological and psychiatric disease. Cell Mol Life Sci. 72(18):3489-506.
IGP Symposium. 2017.
“Development of Small Molecule Translational Activators of Glutamate Transporter, EAAT2, for Treatment of ALS.” Presented at 2015 OSU Life Sciences Interdisciplinary Graduate Programs Symposium.
5th Annual Neuroscience Signature Program Poster Day; Temporal emergence of abnormal behaviors in a mouse model of MeCP2 duplication syndrome.